Volume : 13, Issue : 08, August – 2026
Title:
DUAL-TARGET INHIBITORS IN DRUG-DISCOVERY:RATIONALE, ADVANCES, AND FUTURE PERSPECTIVES
Authors :
Omkar Rai*, Lakhan Kumar Soni, Soma Sekhar Pulamarasetti*, Deepshikha Dey, Vishesh Kumar Prajapati
Abstract :
Dual-target inhibitors are single small molecules intentionally designed to modulate two therapeutically relevant proteins, enzymes, receptors, or signaling nodes within one pharmacological intervention. The strategy extends the polypharmacology paradigm and is especially attractive for complex diseases in which pathway redundancy, compensatory signaling, disease heterogeneity, and acquired resistance weaken single-target therapy. A dual inhibitor can provide coordinated target coverage and synchronized exposure, while potentially simplifying pharmacokinetic management compared with two independent drugs. nevertheless, intentional duality is not equivalent to nonspecific promiscuity: both target interactions should contribute to efficacy at clinically achievable exposure while important antitargets remain controlled. Here, we examine examines the biological rationale for target pairing; pharmacophore fusion, linker-based hybridization, scaffold hopping, repurposing, and phenotypic screening; computational methods including docking, pharmacophore modeling, molecular dynamics, machine learning, and network analysis; and the medicinal-chemistry optimization of potency balance, selectivity, ADME, and safety. Representative programs are discussed in oncology, neurodegeneration, inflammation, infectious disease, and metabolic disorders, with emphasis on PI3K/mTOR, HDAC/PI3K, BET/kinase, PARP/HDAC, COX/LOX, and AChE/MAO-B strategies. The field has generated extensive preclinical evidence, but movement into clinical use remains comparatively limited. Future progress will depend on biologically justified target pairs, quantitative target-balance criteria, biomarker-led development, human-relevant models, chemical proteomics, and AI-assisted multi-objective design.
Keywords: dual-target inhibitor; multitarget drug-discovery; polypharmacology; multi-target-directed ligand; medicinal chemistry; target balance; pharmacophore hybridization; molecular docking; molecular dynamics; machine learning; ADME; drug resistance.
Cite This Article:
Please cite this article in press Omkar Rai et al., Dual-Target Inhibitors In Drug-Discovery:Rationale, Advances, And Future Perspectives., Indo Am. J. P. Sci, 2026; 13(08).
REFERENCES:
1. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57:7874–7887. doi:10.1021/jm5006463.
2. Bolognesi ML, Cavalli A. Multitarget drug discovery and poly pharmacology. Chem Med Chem. 2016;11:1190–1192. doi:10.1002/cmdc.201600161.
3. Proschak E, Stark H, Merk D. Poly pharmacology by design: a medicinal chemist’s perspective on multitarget drugs. J Med Chem. 2019;62:420–444.
4. Ryszkiewicz P, Malinowska B, Schlicker E. Polypharmacology: promises and new drugs in 2022. Pharmacol Rep. 2023;75:755–770.
5. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–690.
6. Hopkins AL. Pharmacology: the network pharmacology revolution. Nat Rev Drug Discov. 2008;7:727–738.
7. Morphy R, Rankovic Z. Fragments, network biology and designing multi-target drugs. J Med Chem. 2005;48:6523–6537.
8. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004;9:641–651.
9. Medina-Franco JL, Giulianotti MA, Welmaker GS, Houghten RA. Shifting from the single to the multi-target paradigm in drug discovery. Drug Discov Today. 2013;18:495–501.
10. Raghavendra NM, Pingili D, Kadasi S, Mettu A, Prasad SVUM. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Chem. 2018;143:1277–1300. doi:10.1016/j.ejmech.2017.10.021.
11. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–644.
12. Lliu YN, Wan RZ, Liu ZP. Recent developments of small molecule PI3K/mTOR dual inhibitors. Mini Rev Med Chem. 2013;13(14):2047-2059. doi:10.2174/13895575113136660105. PMID:24195664.
13. Shi F, Wang M, Wang Z, et al. Recent advances in dual PI3K/mTOR inhibitors for tumour treatment. Front Pharmacol. 2022;13:875372. doi:10.3389/fphar.2022.875372. PMID:35614940.
14. Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15:273–291.
15. Caner A, et al. Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy. J Med Chem. 2020. doi:10.1021/acs.jmedchem.0c00491.
16. Peng X, Sun Z, Kuang P, Chen J. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. Eur J Med Chem. 2020;208:112831.
17. Feng L, Wang G, Chen Y, et al. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: a review from medicinal chemistry perspectives. Med Res Rev. 2022;42:710–743. doi:10.1002/med.21859.
18. Haque S, et al. Dual inhibitors of histone deacetylases and other cancer-related targets: a pharmacological perspective. Biochem Pharmacol. 2020.
19. Morphy R, Rankovic Z. Designed multiple ligands. J Med Chem. 2005;48:6523–6537.
20. Peters JU. Polypharmacology—foes or friends? J Med Chem. 2013;56:8955–8971.
21. Talevi A. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach”. Front Pharmacol. 2015;6:205.
22. Csermely P, Ágoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help. Trends Pharmacol Sci. 2005;26:178–182.
23. Mestres J, Gregori-Puigjané E. Conciliating binding efficiency and polypharmacology. Trends Pharmacol Sci. 2009;30:470–476.
24. Berenstein A, et al. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. Expert Opin Drug Discov. 2018.
25. Lavecchia A, Cerchia C. In silico methods to address the challenges related to polypharmacology and drug repurposing. Front Pharmacol. 2016;7:298.
26. Bolognesi ML. Harnessing polypharmacology with medicinal chemistry. ACS Med Chem Lett. 2013;4:968–969.
27. Royo M, et al. Multi-target-directed ligands: a strategy for the treatment of multifactorial diseases. Curr Med Chem. 2017.
28. Geldenhuys WJ, et al. Rational design of multitarget-directed ligands for neurodegenerative diseases. Future Med Chem. 2014.
29. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA. 2003;100:7977–7982.
30. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175–181.
31. Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012;486:361–367.
32. Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drug-target network. Nat Biotechnol. 2007;25:1119–1126.
33. Frantz S. Drug discovery: playing dirty. Nature. 2005;437:942–943.
34. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6:881–890.
35. Gaulton A, Hersey A, Nowotka M, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45:D945–D954.
36. Wang Y, Bryant SH, Cheng T, et al. PubChem BioAssay: 2017 update. Nucleic Acids Res. 2017;45:D955–D963.
37. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage. Nucleic Acids Res. 2019;47:D607–D613.
38. Vogt I, Mestres J. Drug-target identification through drug effects on the transcriptome. Curr Opin Pharmacol. 2010;10:633–638.
39. Cereto-Massagué A, Guasch L, Valls C, et al. Decoding molecular polypharmacology across chemical space. Nat Commun. 2017;8.
40. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18:463–477.
41. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17:97–113.
42. Bender A, Cortes-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Drug Discov Today. 2021;26:2017–2020.
43. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180:688–702.e13.
44. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37:1038–1040.
45. Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. Nat Mach Intell. 2020;2:573–584.
46. Ertl P, Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform. 2009;1:8.
47. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–562.
48. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–635.
49. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7–24.
50. Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol. 2015;23:98–107.
51. Sabbah DA, Brattain MG, Zhong H. Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? Curr Med Chem. 2011;18(36):5528-5544. doi:10.2174/092986711798347298. PMID:22172063.
52. Lliu YN, Wan RZ, Liu ZP. Recent developments of small molecule PI3K/mTOR dual inhibitors. Mini Rev Med Chem. 2013;13(14):2047-2059. doi:10.2174/13895575113136660105. PMID:24195664.
53. Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents. Eur J Med Chem. 2022.
54. Zeng W, Zhang Z, Li K, Yin Y, Dong S, Ma M. HDAC and PI3K dual inhibitors in the treatment of cancers: current status, trends, and solutions. Eur J Med Chem. 2026;304:118511. doi:10.1016/j.ejmech.2025.118511. PMID:41453303.
55. Discovery of (S)-N1-(thiazol-2-yl)pyrrolidine-1,2-dicarboxamide derivatives targeting PI3Kα/HDAC6. Bioorg Med Chem Lett. 2023;129462. doi:10.1016/j.bmcl.2023.129462.
56. Pathak C, Kabra UD. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer’s disease. Bioorg Chem. 2024;144:107152. doi:10.1016/j.bioorg.2024.107152.
57. Advancements in the development of multi-target directed ligands for the treatment of Alzheimer’s disease. Bioorg Med Chem. 2022;66:116742. doi:10.1016/j.bmc.2022.116742.
58. Multi-target-directed ligands in Alzheimer’s disease treatment. Curr Med Chem. 2012.
59. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51:347–372.
60. León R, García AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev. 2013;33:139–189.
61. Youdim MBH, Buccafusco JJ. Multi-target strategies in Alzheimer’s and Parkinson’s diseases. J Neural Transm. 2005;112:519–537.
62. Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67:195–203.
63. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27–50.
64. Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease. Expert Opin Ther Pat. 2023. doi:10.1080/14756366.2023.2270781.
65. Dual inhibitors of acetylcholinesterase and monoamine oxidase-B for the treatment of Alzheimer’s disease. Review. 2025.
66. Patrignani P, Tacconelli S. Is selective inhibition of cyclooxygenase-2 all that we need to spare the heart? Trends Pharmacol Sci. 2002;23:250–255.
67. Marnett LJ. Aspirin and the potential role of prostaglandins in cancer prevention. J Natl Cancer Inst. 2002;94:252–253.
68. Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 and 5-lipoxygenase as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem. 2003;38:645–659. doi:10.1016/S0223-5234(03)00115-6.
69. Cuzzolin L, et al. New trends in dual 5-LOX/COX inhibition. Curr Med Chem. 2002. doi:10.2174/0929867024606713.
70. Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: a structure-based approach. Eur J Med Chem. 2018.
71. Aliabadi A, Khanniri E, Mahboubi-Rabbani M, Bayanati M. Dual COX-2/15-LOX inhibitors: a new avenue in the prevention of cancer. Eur J Med Chem. 2023;261:115866. doi:10.1016/j.ejmech.2023.115866.
72. Agrawal N. A comprehensive review on the advancements of dual COX-2/5-LOX inhibitors as anti-inflammatory drugs. Chem Biol Drug Des. 2025;105:e70114. doi:10.1111/cbdd.70114.
73. Recent advances in dual COX/LOX inhibitor design (2020–2024). Review. 2026.
74. Waring MJ. Defining optimum lipophilicity and molecular weight for drug design. Bioorg Med Chem Lett. 2009;19:2844–2851.
75. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615–2623.
76. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
77. Leeson PD. Molecular inflation, attrition and the rule of five. Adv Drug Deliv Rev. 2016;101:22–33.
78. Yang Y, et al. Rethinking therapeutic strategies of dual-target drugs: an update on pharmacological small-molecule compounds in cancer. Med Res Rev. 2024. doi:10.1002/med.22057.
79. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. J Med Chem. 2019. doi:10.1021/acs.jmedchem.9b00726.
80. Dual kinase-bromodomain inhibitors in anticancer drug discovery: a structural and pharmacological perspective. J Med Chem. 2016. doi:10.1021/acs.jmedchem.6b00438.
81. Dual inhibitors of histone deacetylases and other cancer-related targets: a pharmacological perspective. Biochem Pharmacol. 2020.
82. Hybrids from farnesylthiosalicylic acid and hydroxamic acid as dual Ras-related signaling and HDAC inhibitors. ChemMedChem. 2015. doi:10.1002/cmdc.201500019.
83. Dual-targeting strategy in cancer therapy: emerging role of pyrrolopyrimidine scaffolds. ChemMedChem. 2026.
84. Strategies for multi-target drug discovery. In: Polypharmacology. Wiley. 2025. doi:10.1002/9781394182862.ch16.
85. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. Expert Opin Drug Discov. 2018.
86. Talevi A, Bellera CL. Challenges and opportunities in multitarget drug design. Future Med Chem. 2012.
87. Delmas F, et al. Dual-target drug design: medicinal chemistry and pharmacology perspectives. Drug Discov Today. 2019.
88. Berenstein A, et al. Polypharmacology and the efficacy-toxicity balance in anticancer drug discovery. Expert Opin Drug Discov. 2018.
89. Peters JU. Polypharmacology: implications for drug discovery and development. J Med Chem. 2013.
90. Shi D, Li X. Strategies for multi-target drug discovery. Polypharmacology. Wiley. 2025.
91. Shi F, Wang M, Wang Z, et al. Recent advances in dual PI3K/mTOR inhibitors for tumour treatment. Front Pharmacol. 2022;13:875372. doi:10.3389/fphar.2022.875372. PMID:35614940.
Volume : 13, Issue : 08, August – 2026
Title:
EVALUATION OF ANTIHYPERLIPIDEMIC ACTIVITY OF SAPINDUS EMARGINATUS IN RATS
Authors :
Chinthala Jamima*, Dr.R.narasimha Rao, Dr.N. Raghunandhan
Abstract :
Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Sapindus emarginatus against hyperlipidemia. In this model of Hyperlipidemia, 30 adult male wistar rats (200-250gms) were evenly divided into 5 groups in both groups. Group-1 and Group-2 served as untreated and model controls respectively, while Group-3, 4 and 5 were the treatments groups which were simultaneously treated with standard, 100 and 200 mg/kg extract respectively along with High Fat Diet. On last day, blood samples for biochemical parameters, were obtained under inhaled diether anaesthesia. The outcomes of this study were expressed as mean standard error and data were evaluated by using analysis of variance followed by multiple comparisons. Oral administration of 100 mg/ kg and 200mg/kg body weight of Methanolic extract residual fraction of Moringa oleifera. Leaves exhibited a significant reduction (P < 0.01) in serum lipid parameters such as triglycerides, total cholesterol, low density lipoprotein (LDL), very LDL and increase in high density lipoprotein in hyperlipidemic rats when compared with hyperlipidemic control in both models. Our results demonstrated that Methanolic extract fraction of Sesbania grandiflora. Possessed significant antihyperlipidemic activity.
Keywords: Sesbania grandiflora, Cholesterol, LDL, triglycerides and antihyperlipidemic activity.
Cite This Article:
Please cite this article in press Chinthala Jamimaet al., Evaluation of Antihyperlipidemic activity of Sapindus Emarginatus in rats,, Indo Am. J. P. Sci, 2026; 13(08).
REFERENCES:
1. Amit G, Vandana S, Sidharth M. HYPERLIPIDEMIA: An Updated Review. Inter J of Biopharma & Toxicol Res 2011;1:81-89.
2. Virchow RP, Thrombose IG. In Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt-am-Main, Meidinger Sohn & Company 1856, S 458-564.
3. Ankur rohilla, Nidhi Dagar, Seema Rohilla, Amarjeet Dahiya, Ashok Kushnoor. HYPERLIPIDEMIA- a deadly pathological condition. Inter J Curr Pharma Res 2012;4:15-18
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-77.
5. Grundy SM, Vega GL. Hypertriglyceridemia: causes and relation to coronary heart disease – Semin. Thromb. Hemost 1988;14:249-64.
6. Dargel R. Lipoproteins and the etiopathogenesis of atherosclerosis. Zentralbl Allg Pathol 1989; 135: 501-504.